Home - Veloxis - Transplant Patients
25 hours ago portal.citushealth.com >> Go To The Portal
Why Veloxis Pharmaceuticals?
portal.citushealth.com
How do I sign up for Veloxis transplant support?
Veloxis is dedicated to improving patient care through innovative therapies. MeltDose ® Technology. Veloxis developed a proprietary, patented drug delivery technology called MeltDose to enhance the oral bioavailability and control the release of a drug, especially low water-soluble or -insoluble drugs.
What is Veloxis'kidney transplant program?
Please visit www.velox-global.com for disclosures including terms and conditions governing your account. Account carried by Velox Clearing LLC.
What is the Tol patient portal?
Test results can be accessed and reviewed through your patient portal. If you’re having issues locating your patient portal, the portal locator will help you find it. If you’re having issues logging into your patient portal, please contact your medical provider’s office for support.
How to contact Veloxis Transplant Support?
Your practice or patient calls 1-844-VELOXIS (835-6947) and selects the appropriate phone prompt for Veloxis Transplant Support (press 3). The phone prompt will direct the caller to a financial support representative who will review the process and guidelines for PAP eligibility.
How long is the PAP trial?
Eligibility for PAP is determined on a per-patient basis, so time to approval may vary. A 30-day free trial voucher is available for all patients, regardless of eligibility, who may require a longer benefits investigation.
Transplant
ENVARSUS XR is indicated for the prophylaxis of organ rejection in de novo kidney transplant patients in combination with other immunosuppressants.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about ENVARSUS XR?
800-538-9552
To create ant then access the MHS GENESIS Patient Portal, visit https://patient.mhsgenesis.health.mil
What are the chief benefits of MHS GENESIS?
MHS GENESIS is the first Department of Defense-wide electronic health record to be used by all military treatment facilities. By the time that MHS GENESIS is fully implemented throughout all of the DoD, patients will be able to receive care from any military treatment facility knowing that their health records will follow them.
How is MHS GENESIS different from CAL MED's current electronic health record systems?
Like all Army military treatment facilities, CAL MED currently uses several electronic health record systems for inpatient records, outpatient records, emergency room records, and other areas of care. While care teams can view patients' records in the different systems, this requires extra time to navigate all of the records.
What will I notice about what's new with MHS GENESIS?
The primary difference that patients will notice is the Patient Portal. While receiving care at MTFs which use MHS GENESIS, patients will no longer use RelayHealth and Tricare Online except for limited functions, such as requesting new providers.
When will I be able to start using the MHS GENESIS Patient Portal?
While patients may be able to log on to the Patient Portal and explore it during the weeks leading up to the transition to MHS GENESIS, the Patient Portal will not be active until September 7, 2019.
When patients move, will their new military treatment facilities be using MHS GENESIS?
The Department of Defense has a multi-year plan for all military treatment facilities to transition to MHS GENESIS. CAL MED is in the second wave of military treatment facility to transition to MHS GENESIS.
TOL Secure Patient Portal
The TOL Patient Portal (also referred to as "TRICARE Online" or "TOL") is the current secure patient portal that gives registered users access to online health care information and services at military hospitals and clinics.
MHS GENESIS Patient Portal
MHS GENESIS is the new secure patient portal for TRICARE. It will eventually deploy to all military medical and dental facilities worldwide and replace the TOL Patient Portal.
Using MHS GENESIS and TOL Together
If you’re already a registered user on the TOL Secure Patient Portal, MHS GENESIS works much the same way.
Log in to your Secure Patient Portal
If your military hospital or clinic uses TOL, click here to log in: >>TRICARE Online
Corporate Development
If you are interested in discussing licensing or business opportunities, please email us at bd@veloxis.com
Media, Corporate and Investor Communication
Veloxis aims to be as responsive to media inquiries as possible. If you require further information, would like an interview with Veloxis Management, or would like to be added to our media distribution list, please email us at ir@veloxis.com
Customer Service and Product Inquires
For all U.S. customer service inquires, complaints, or product inquires, please contact:
Need Help Paying for Your Medicines?
At Veloxis, we’re dedicated to ensuring that all patients, regardless of circumstance, receive their medications.
Indications and Usage
ENVARSUS XR is indicated for the prophylaxis of organ rejection in de novo kidney transplant patients in combination with other immunosuppressants. ENVARSUS XR is also indicated for the prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with o…
Important Safety Information
- WARNING: MALIGNANCIES AND SERIOUS INFECTIONS Increased risk for developing serious infections and malignancies with ENVARSUS XR or other immunosuppressants that may lead to hospitalization or death
Warnings and Precautions
- Lymphoma and Other Malignancies:Immunosuppressants, including ENVARSUS XR, increase the risk of developing lymphomas and other malignancies, particularly of the skin. Post-transplant lymphoproliferative disorder (PTLD), associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients. Serious Infections:Immunosuppressants, inclu…
Adverse Reactions
- De Novo kidney transplant patients: Most common adverse reactions (incidence ≥15%) reported with ENVARSUS XR are diarrhea, anemia, urinary tract infection, hypertension, tremor, constipation, diabetes mellitus, peripheral edema, hyperkalemia and headache. Conversion of kidney transplant patients from immediate-release tacrolimus: Most common adverse reaction…
Use in Specific Populations
- Pregnancy:Based on postmarketing surveillance, registry and animal data may cause fetal harm. Advise pregnant women of the potential risk to the fetus. Nursing Mothers:Tacrolimus is present in human milk. Discontinue drug or nursing, taking into account the importance of drug to the mother. Females and Males of Reproductive Potential: Advise female and male patients of repro…
Popular Posts:
- 1. ievf patient portal
- 2. provider patient portal hq
- 3. mycw patient portal
- 4. duncan regional patient portal
- 5. mybmh org patient portal
- 6. joop offerman patient portal
- 7. mwcwh patient portal
- 8. southern sierra medical clinic ridgecrest patient portal
- 9. www.specialistsinpaincare.com patient portal
- 10. patient portal tower radiaiology